View Author
patient disease bilirubin serum glucosidase study mutation treatment muscle pompe disease level serum bilirubin 4 patients rotterdam pompe enzyme rhaglu month hfe mutations rabbit glycogen therapy glucosidase activity 40 mg /kg serum bilirubin levels enzyme replacement therapy rabbit milk netherland effect mortality production bilirubin levels h 63d mutation 20 mg /kg erasmu genotype women serum iron indices development activity hemochromatosi analysis erasmus mc storage hfe genotypes signi ficantly infant hfe c 282y c 282y heterozygotes alpha-glucosidase c 282y mutation muscle function 4 years protein oxidative stress erasmus mc-sophia function number 1 year 12 weeks reuser aj baseline table lysosomal signi fabry disease homozygote patient 3 van der ploeg iron overload infusion motor 110- kda precursor subject h 63d homozygotes tissue heterozygote efficacy antioxidant inclusion
2 Most Recent Publications
|
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk
(Article)
Hout, J.M.P. van den Sibbles, B. Corven, E.J. van Hirtum, H. van Kamphoven, J.H.J. Ploeg, A.T. van der Hove, J. van Arts, W.F.M. Doorn, P.A. van Klerk, J.B. de Loonen, M.C.B. Vulto, A.G. Brakenhoff, J.P. Kroos, M.A. Hop, W.C.J. Winkel, L.P.F. Jong, G. de Cromme-Dijkhuis, A.H. Weisglas-Kuperus, N. Reuser, A.J.J. Boer, M. Smeitink, J.A. Diggelen, O.P. van Voort, E. van der |
2004-01-01
|
|
Does Bilirubin protect against hemochromatosis gene (HFE) related mortality?
(Article)
Alizadeh, B.Z. Njajou, O.T. Houwing-Duistermaat, J.J. Jong, G. de Vergeer, J.M. Hofman, A. Duijn, C.M. van Pols, H.A.P. |
2004-01-01
|